Answers are grounded in this paper and cite their sources.
During a cluster-randomized clinical trial for trachoma in Ethiopia, two rounds of adverse event surveillance were performed in a random sample of communities after community-wide mass azithromycin treatment. The prevalence of any reported adverse event ranged from 4.9% to 7.0% in children 1-9 years of age and from 17.0% to 18.7% in persons ≥ 10 years of age. Adverse events appeared to cluster by household and perhaps by village. Mass azithromycin distributions were well tolerated in this setting.
No takes yet. Share an insight, caveat, or question.
Ayele et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: